Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Azercabtagene zapreleucel (azer-cel)
Azercabtagene zapreleucel · 1 trial · 1 indication
DLT will be determined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
| Arm | Type | Description |
|---|---|---|
| Azer-cel | EXPERIMENTAL | Participants will receive single dose of intravenous (IV) infusion of azer-cel at different dose levels, on Day 0 of the treatment period. |
| Name | Type | Description |
|---|---|---|
| Azercabtagene zapreleucel (azer-cel) | DRUG | IV infusion |
Inclusion Criteria: PMS and RMS inclusion criteria: 1. Age 18 years to ≤60 years (inclusive) at screening. 2. Expanded Disability Status Scale (EDSS) score 3.0 - 6.5 (inclusive) at screening. 3. Diagnosis of primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (n...
Azercabtagene zapreleucel (azer-cel) is an investigational cell therapy being studied for the treatment of B-cell mediated autoimmune disorders. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Azercabtagene zapreleucel is a cell therapy that targets B cells, which are implicated in autoimmune disorders. By targeting these cells, it aims to modulate the immune response in conditions where B cells drive disease pathology.
Azercabtagene zapreleucel is being developed by TG Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol TGTX. The company is conducting clinical trials to evaluate the safety and activity of this investigational therapy.
Azercabtagene zapreleucel is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency and is still being studied in clinical trials.
Azercabtagene zapreleucel is being evaluated in a Phase 1 clinical trial with the identifier NCT06680037. This study is assessing the safety and clinical activity of azer-cel in participants with B-cell mediated autoimmune disorders and is currently recruiting in the United States.
Yes, Azercabtagene zapreleucel is also known as azer-cel. The shorter name is used in clinical trial documentation and communications to refer to the same investigational cell therapy.